What Is Low-Grade Bladder Cancer? Symptoms & Treatment

Low-grade bladder cancer is the most common form of bladder cancer, and it is almost always confined to the bladder’s inner lining rather than invading the muscle wall beneath it. These tumors tend to grow slowly and carry a very low risk of spreading to other organs, but they come back frequently, with about half of patients experiencing a recurrence within four years. That combination of low danger and high recurrence makes low-grade bladder cancer less a one-time crisis and more a chronic condition that can shadow a person for years through repeated procedures, surveillance visits, and ongoing anxiety.

What Makes a Bladder Tumor “Low-Grade”

When a pathologist examines bladder tumor tissue under a microscope, they assign it a grade based on how abnormal the cells look. Low-grade cells still resemble normal bladder lining cells fairly closely, with relatively orderly architecture. High-grade cells, by contrast, appear more disorganized and aggressive. This distinction matters because it predicts behavior: low-grade tumors tend to recur but rarely invade deeper tissue, while high-grade tumors are more likely to burrow into the bladder muscle and potentially spread. At the molecular level, the two types are driven by different genetic events. Low-grade tumors are characterized by a high rate of FGFR3 mutations and chromosome 9 changes, whereas high-grade and muscle-invasive tumors are more commonly associated with TP53 mutations.¹

There is also a borderline category sometimes called “papillary urothelial neoplasm of low malignant potential,” or PUNLMP. These look slightly more abnormal than normal tissue but not quite abnormal enough to be called low-grade cancer. In practice, this label has fallen out of favor because the appearance overlaps heavily with low-grade tumors and the treatment is essentially the same.² A study comparing the two found that patients labeled with PUNLMP had a somewhat lower recurrence rate than those labeled with low-grade carcinoma, but there was no meaningful difference in progression to more dangerous disease.³ So if your pathology report says PUNLMP rather than low-grade cancer, the practical outlook is similar.

Symptoms That Lead to Diagnosis

The hallmark symptom of bladder cancer, whether low-grade or high-grade, is blood in the urine. Visible blood, called gross hematuria, is by far the strongest predictor. A large primary-care study found that visible hematuria carried an odds ratio of 34 for bladder cancer, meaning it was far more strongly linked to a bladder cancer diagnosis than any other symptom.⁴ Painful urination, recurrent urinary tract infections, and abdominal pain were also associated with the disease, but their predictive power was much weaker.

Blood in the urine can be alarming, but it is worth knowing that most people who see it do not have cancer. Among patients aged 60 or older with visible hematuria, only about 2.6% turned out to have bladder cancer in that same study. Still, the symptom always warrants investigation. Sometimes the blood is microscopic, discovered only on a routine urine test, and that too should be followed up. Low-grade tumors do not usually cause pain or other dramatic symptoms, so hematuria may be the only early sign.

How the Diagnosis Is Made

If bladder cancer is suspected, the standard workup involves cystoscopy, a procedure in which a thin camera is inserted through the urethra to visually inspect the bladder lining. This is the most reliable way to spot tumors. Urine cytology, where a pathologist examines shed cells in the urine under a microscope, is sometimes done alongside it, but cytology has a known weakness: it is poor at detecting low-grade tumors.⁵ In one study of patients being monitored for low-grade disease, urine cytology was positive in only about 20% of confirmed recurrences and changed clinical management in less than 1% of all cases.⁶

Researchers have been developing urine-based molecular tests that could do better. One approach uses methylation biomarkers, measuring chemical modifications on DNA shed into the urine. A panel of two such markers was able to detect bladder cancer with a sensitivity of about 76% and discriminate between high-grade and low-grade tumors with reasonable accuracy.⁷ These tests are not yet routine, but they represent a push toward reducing the number of invasive procedures patients must undergo.

Treatment After Diagnosis

The first-line treatment for a newly discovered low-grade bladder tumor is transurethral resection of bladder tumor, abbreviated TURBT. It is both a diagnostic and therapeutic procedure: the surgeon passes an instrument through the urethra, scrapes or cuts the tumor off the bladder wall, and sends the tissue to a pathologist to confirm the grade and stage. No external incisions are needed. For most patients with low-grade disease, TURBT is the only surgery required, though it often needs to be repeated when tumors come back.⁸

Right after the resection, many patients receive a single instillation of chemotherapy directly into the bladder. The drug is delivered through a catheter and held in the bladder for about an hour. An updated meta-analysis of over 2,500 patients found that this one-time post-surgical chemotherapy dose prolongs the time before a recurrence and reduces early recurrence rates.⁹ A network meta-analysis found that several drugs were effective in this role, including mitomycin C, epirubicin, and pirarubicin, with pirarubicin being the only agent in that analysis also linked to reduced disease progression.¹⁰

Beyond that single post-operative dose, the International Bladder Cancer Group recommends being cautious about additional intravesical therapy for low-grade tumors. Extended courses of intravesical chemotherapy or immunotherapy like BCG are typically reserved for patients whose risk profile warrants them, and many patients with straightforward low-grade disease do not need them.¹¹

Recurrence and Progression

The defining frustration of low-grade bladder cancer is recurrence. About half of patients with low-risk non-muscle-invasive disease experience a recurrence within four years.¹² Each recurrence usually means another TURBT. Some patients go through this cycle many times over a decade or more.

Progression, meaning the tumor upgrading to high-grade or invading the muscle, is a different story. That same study found that high-risk recurrence (defined as the first recurrence of a high-grade or deeper tumor) occurred in about 6% of patients overall and only about 3% after five years of follow-up. A separate study tracking patients through multiple recurrences found that the number of previous recurrences was not a significant predictor of progression, meaning that having a tumor come back repeatedly did not necessarily mean it was becoming more dangerous.¹³

That said, long-term data suggest the assumption that low-grade disease is essentially harmless may be slightly too optimistic. One study with extended follow-up challenged the idea that low-grade bladder cancer “nearly never progresses to lethal disease,” though it also noted that the risk of dying from it is extremely low in patients who remain recurrence-free for the first five years.¹⁴

Active Surveillance as an Alternative to Immediate Surgery

Because many low-grade recurrences are small, slow-growing, and unlikely to progress, some specialists now offer active surveillance instead of immediately resecting every tiny recurrence. The idea is to watch a small, papillary-appearing recurrence with regular cystoscopies rather than automatically scheduling another trip to the operating room. A systematic review found that active surveillance is feasible with low progression rates, and tumor growth or changes in cytology serve as triggers for intervention.¹⁵ Long-term data from one active surveillance program confirmed that it is oncologically safe over extended follow-up in carefully selected patients.¹⁶

An international Delphi consensus panel outlined criteria for who is a reasonable candidate. Active surveillance should be offered only to patients who are asymptomatic, have papillary-appearing tumors, and have lesions under 1 cm in diameter. Patients need to be fully informed about the trade-offs: they may avoid surgery, but they commit to closer monitoring, typically more frequent cystoscopies, and they accept a small residual risk that a tumor could progress before the next check.¹⁷

The Surveillance Treadmill

Whether or not you opt for active surveillance of recurrences, low-grade bladder cancer requires ongoing cystoscopic monitoring. Most recurrences in low-risk disease happen within the first two years, with one study finding that 80% occurred in that window. The authors recommended cystoscopy every three months during the first two years, even if no recurrence appeared at the initial follow-up check, because spacing it out further might delay catching a recurrence by six months or more.¹⁸ After the initial years pass without recurrence, the interval between checks is typically lengthened.

This schedule takes a toll. A survey-based study found that about two-thirds of patients undergoing cystoscopic surveillance experienced some degree of procedural discomfort or worry, and patients consistently reported anxiety leading up to each cystoscopy.¹⁹ The relief after a clear result was real, with all participants in that study reporting improvement in well-being after the procedure. But the cycle repeats: anxiety builds before the next appointment, peaks in the waiting room, and only dissipates when the results come back clear. A separate randomized study comparing flexible and rigid cystoscopy found that the procedure generally did not damage overall quality of life or sexual function,²⁰ but the intermittent psychological burden is something patients should be prepared for.

The Financial Weight of a “Low-Risk” Cancer

Bladder cancer, as a category, is the most expensive malignancy per patient, largely because of this prolonged cycle of treatment and surveillance.²¹ Low-grade disease drives a large share of that cost. One study estimated that roughly 30,000 new low-grade Ta cases are diagnosed annually in the United States alone, and it documented widespread overuse of imaging, cystoscopy, and cytology in patients whose low-risk status did not necessarily justify such intensive monitoring.²²

One cost-saving approach involves treating small, obvious low-grade recurrences with office-based fulguration (burning off the tumor under local anesthesia in a clinic) rather than a full TURBT in the operating room. A Canadian study estimated savings of about $7,000 per patient over the follow-up period using this approach.²³ The procedure is quicker, avoids general anesthesia, and produces comparable outcomes for these small, well-characterized tumors.

Newer Treatment Approaches

One of the more promising developments for low-grade disease is chemoablation, in which a drug is instilled directly into the bladder to dissolve the tumor without surgery. A phase 2b trial tested UGN-102, a gel formulation of mitomycin that is instilled into the bladder and slowly releases the drug as it warms to body temperature. About 65% of patients achieved a complete response at three months, and of those responders, roughly 73% were still disease-free at nine months and 61% at one year.²⁴ A subsequent phase 3 randomized trial has been conducted comparing this drug (with or without TURBT) against TURBT alone.⁸ If chemoablation proves durable, it could spare many patients the repeated operating-room visits that define their disease experience.

Risk Factors and Who Gets Low-Grade Bladder Cancer

Cigarette smoking is the single most important risk factor for bladder cancer in industrialized countries.²⁵ Smoking elevates risk across the entire clinical spectrum, but a large epidemiological study found that after adjusting for tumor stage, smoking was associated with a somewhat higher risk of low-grade than high-grade tumors. Heavy current smokers had relative risks of about 3.0 for non-invasive disease and 5.2 for invasive disease, indicating that while smoking promotes all forms, the heaviest smoking is more strongly linked to the more advanced presentations.²⁶

Occupational exposure to aromatic amines remains a well-established cause. These chemicals are found in the dye, rubber, chemical, and leather industries, as well as in hair dyes, paints, motor vehicle exhaust, and some industrial emissions.²⁷ A systematic review found the highest bladder cancer risks among workers exposed to aromatic amines, including tobacco workers, dye workers, hairdressers, printers, and leather workers, as well as those exposed to polycyclic aromatic hydrocarbons, such as chimney sweeps, aluminum workers, and oil/petroleum workers.²⁸ Organic solvents including benzene, toluene, and xylene have also been linked to elevated bladder cancer risk.²⁹ Occupational risk, unlike smoking, was found to affect non-invasive and invasive disease at comparable rates, suggesting these exposures promote tumors regardless of grade or stage.²⁶

Quitting Smoking After Diagnosis

If you are diagnosed with low-grade bladder cancer and still smoke, quitting is one of the most direct things you can do to improve your outlook. A systematic review and meta-analysis found that smoking cessation may reduce the risk of bladder cancer recurrence, though the authors noted that more research is needed to fully quantify the benefit.³⁰ Given that low-grade bladder cancer already recurs frequently, reducing any additional fuel for those recurrences is worth the effort. Doctors should be raising the topic at diagnosis, though in practice it does not always happen as consistently as it should.

When Other Cancers Look Like Low-Grade Bladder Cancer

One diagnostic pitfall worth mentioning is under-grading. In the phase 2b chemoablation trial described earlier, five of the 22 patients who did not respond to treatment turned out to have high-grade tumors that had been misjudged as low-grade at screening.²⁴ Under-grading can happen because visual appearance during cystoscopy does not always match what the pathologist sees under the microscope, and even urine cytology cannot reliably distinguish PUNLMP from low-grade carcinoma.³¹ This is one reason TURBT with tissue sampling remains the gold standard. Active surveillance or chemoablation strategies that skip surgical biopsy must be carefully calibrated to avoid missing a tumor that is more dangerous than it appears.